Use of sacubitril/valsartan in patients with heart failure: evidence from the real world
CONCLUSIONS: The persistence of treatment 1 year after starting sacubitril/valsartan was not high, and a small proportion of patients reached the target dose of the drug. Nontitration of the drug dose was common.PMID:38051633 | DOI:10.1080/14656566.2023.2287667 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - December 5, 2023 Category: Drugs & Pharmacology Authors: Luis Fernando Valladales-Restrepo Nicol ás Sánchez-Ramírez Andr és Felipe Usma-Valencia Santiago Vel ásquez-Quirama Manuela Henao-Mart ínez Jorge Alejandro Castro-Rodriguez Andr és Gaviria-Mendoza Manuel Enrique Machado-Duque Jorge Enrique Machado- Source Type: research
The landscape of pathophysiology guided therapeutic strategies for gout treatment
Expert Opin Pharmacother. 2023 Dec 1:1-11. doi: 10.1080/14656566.2023.2291073. Online ahead of print.ABSTRACTINTRODUCTION: Gout is a common autoinflammatory disease caused by hyperuricemia with acute and/or chronic inflammation as well as tissue damage. Currently, urate-lowering therapy (ULT) and anti-inflammatory therapy are used as first-line strategies for gout treatment. However, traditional drugs for gout treatment exhibit some unexpected side effects and are not suitable for certain patients due to their comorbidity with other chronic disease.AREAS COVERED: In this review, we described the pathophysiology of hyperuri...
Source: Expert Opinion on Pharmacotherapy - December 1, 2023 Category: Drugs & Pharmacology Authors: Sai Heng Hao Lin Yan Ye Chang Yang Source Type: research
Novel pharmacotherapy for drug-induced immune hemolytic anemia
Expert Opin Pharmacother. 2023 Dec 1:1-5. doi: 10.1080/14656566.2023.2291075. Online ahead of print.NO ABSTRACTPMID:38037866 | DOI:10.1080/14656566.2023.2291075 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - December 1, 2023 Category: Drugs & Pharmacology Authors: Wilma Barcellini Bruno Fattizzo Source Type: research
What hinders individualized therapy plans for asthma patients?
Expert Opin Pharmacother. 2023 Dec 1:1-4. doi: 10.1080/14656566.2023.2291078. Online ahead of print.NO ABSTRACTPMID:38038661 | DOI:10.1080/14656566.2023.2291078 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - December 1, 2023 Category: Drugs & Pharmacology Authors: Ahmad Z Al Meslamani Source Type: research
The landscape of pathophysiology guided therapeutic strategies for gout treatment
Expert Opin Pharmacother. 2023 Dec 1. doi: 10.1080/14656566.2023.2291073. Online ahead of print.ABSTRACTINTRODUCTION: Gout is a common autoinflammatory disease caused by hyperuricemia with acute and/or chronic inflammation as well as tissue damage. Currently, urate-lowering therapy (ULT) and anti-inflammatory therapy are used as first-line strategies for gout treatment. However, traditional drugs for gout treatment exhibit some unexpected side effects and are not suitable for certain patients due to their comorbidity with other chronic disease.AREAS COVERED: In this review, we described the pathophysiology of hyperuricemia...
Source: Expert Opinion on Pharmacotherapy - December 1, 2023 Category: Drugs & Pharmacology Authors: Sai Heng Hao Lin Yan Ye Chang Yang Source Type: research
Novel pharmacotherapy for drug-induced immune hemolytic anemia
Expert Opin Pharmacother. 2023 Dec 1. doi: 10.1080/14656566.2023.2291075. Online ahead of print.NO ABSTRACTPMID:38037866 | DOI:10.1080/14656566.2023.2291075 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - December 1, 2023 Category: Drugs & Pharmacology Authors: Wilma Barcellini Bruno Fattizzo Source Type: research
What hinders individualized therapy plans for asthma patients?
Expert Opin Pharmacother. 2023 Dec 1. doi: 10.1080/14656566.2023.2291078. Online ahead of print.NO ABSTRACTPMID:38038661 | DOI:10.1080/14656566.2023.2291078 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - December 1, 2023 Category: Drugs & Pharmacology Authors: Ahmad Z Al Meslamani Source Type: research
The landscape of pathophysiology guided therapeutic strategies for gout treatment
Expert Opin Pharmacother. 2023 Dec 1. doi: 10.1080/14656566.2023.2291073. Online ahead of print.ABSTRACTINTRODUCTION: Gout is a common autoinflammatory disease caused by hyperuricemia with acute and/or chronic inflammation as well as tissue damage. Currently, urate-lowering therapy (ULT) and anti-inflammatory therapy are used as first-line strategies for gout treatment. However, traditional drugs for gout treatment exhibit some unexpected side effects and are not suitable for certain patients due to their comorbidity with other chronic disease.AREAS COVERED: In this review, we described the pathophysiology of hyperuricemia...
Source: Expert Opinion on Pharmacotherapy - December 1, 2023 Category: Drugs & Pharmacology Authors: Sai Heng Hao Lin Yan Ye Chang Yang Source Type: research
Novel pharmacotherapy for drug-induced immune hemolytic anemia
Expert Opin Pharmacother. 2023 Dec 1. doi: 10.1080/14656566.2023.2291075. Online ahead of print.NO ABSTRACTPMID:38037866 | DOI:10.1080/14656566.2023.2291075 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - December 1, 2023 Category: Drugs & Pharmacology Authors: Wilma Barcellini Bruno Fattizzo Source Type: research
